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Fact, Fiction, or Evolution: 




The metabolism hypothesis of Alzheimer’s disease (AD) was first proposed in 
1975. In normal aging and very mild AD, the cerebral metabolic rate for oxygen 
(CMRO2) and cerebral blood flow (CBF) remained approximately constant, but 
the metabolism of glucose (CMRglu) declined markedly. This decline in CMRglu 
identified a specific and primary metabolic defect that triggered downstream 
cellular cascades evolving into AD and its characteristic neuropathological lesions. 
These findings led research about AD into the role of insulin resistance that foresaw 
modern trials of insulin for AD treatment. The metabolism hypothesis evolved over 
subsequent decades with improved in-vivo measurement of metabolic parameters 
and AD biomarkers in humans. A more recent model highlights the interrelation-
ships between the default mode network (DMN) and biomarkers such as CMRglu, 
amyloid, and tau. In other words, metabolic conditions related to sustained cortical 
activity during aging throughout the lifetime are conducive to the deposition of 
amyloid. This activity is thought to underlie the “autobiographical self.” These ideas 
and findings motivate aging and AD-research focus on the biochemistry and cell 
biology of cerebral metabolism.
Keywords: dementia, amyloid, tau, cerebral metabolism, default mode networks, 
cerebral energetics, aerobic glycolysis, cognitive aging, functional connectivity
1. Introduction
Hoyer et al. proposed the metabolism hypothesis of AD based on observations 
of normal aging and early AD focusing on the relationships between CMRglu, 
CMRO, and CBF [1–3]. This hypothesis has both weak and strong versions. The 
weak version, not of interest here, suggests that amyloid deposition is an epi-
phenomenon, potentially unrelated to AD; the causative pathophysiology must 
lay elsewhere—perhaps a primary mitochondrial failure. The more interesting 
hypothesis relies on a stronger version: neural activity sustained during resting 
and introspection (i.e., wakefulness [4]) over a lifetime (i.e., the “autobiographical 
self”) drives AD pathology.
A more recent model of the strong version posited sustained metabolic activity 
in the default mode network (DMN) is a substrate for amyloid deposition through 
the mediation of some process related to neural activity [5]. CMRglu declined with 
aging. Since oxidative metabolism was largely preserved, a primary abnormality in 
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the handling of glucose was posited with the observation that aerobic glycolysis (AG) 
declined precipitously during normal aging [6, 7]. Concomitantly, molecular imaging 
of critical biomarkers in AD identified for the first time the distribution of proteins 
such as fibrillar amyloid and tau in the brain, both in asymptomatic healthy elderly 
and in patients with various neurodegenerative disorders including AD [8–10].
Such progress led to the definition and characterization of preclinical and 
clinical AD based on biomarkers for staging [11–14]. To understand the pathophysi-
ology of the hypothesized metabolic dysfunction, understanding the relationships 
between brain metabolism and these neuropathological biomarkers became critical 
during both normal aging and AD. These advances detail the evolution of imaging 
biomarkers along with their relationship to the brain’s structural, metabolic, and 
cognitive dysfunction.
Here, recent findings relevant to aging and AD are reviewed briefly as back-
ground. Current understanding of the development and ontogenesis of biomarkers 
for AD are summarized. Data are integrated with advances in neuroimaging and 
brain metabolism as well as in preclinical models mostly focusing on the resting 
state. These results bear on the metabolism hypothesis of AD. Notable gaps in 
this hypothesis and its relationship to cognitive aging highlight avenues requiring 
further research for progress in the field.
2. Amyloid and tau in aging and AD
Several studies of patients developing dementia (both early and late-onset spo-
radic AD; familial AD) as well as Down’s syndrome show amyloid deposition begins 
decades before overt symptoms of dementia arise [11, 15, 16]. Amyloid deposition 
of plaques, particularly the diffuse type, in AD begins in inferior neocortex with 
spread to other neocortical regions including precuneus, lateral parietal, and frontal 
association neocortices [17, 18]. Amyloid positivity predicts past and future pro-
gressive cognitive decline [19]. Glucose metabolism tends to decline where amyloid 
localizes; it is first seen in preclinical AD, mild cognitive impairment (MCI), and 
early AD using fluorodeoxyglucose (FDG) positron emission tomography (PET) in 
the posterior cingulate cortex (PCC) followed by biparietal involvement [20–22]. 
The steepest increases in amyloid deposition during healthy aging according to 
amyloid PET, thought to measure fibrillar amyloid or neuritic plaques, occurs in 
anterior cingulate cortex (ACC), PCC, precuneus, and temporal cortices [23]. The 
earliest detectable amyloid deposits by PET localize to precuneus, PCC, and medial 
orbitofrontal cortex; these deposits were not associated with atrophy or hypome-
tabolism despite changes in functional connectivity [24].
Although there is some overlap between amyloid deposition and cortical 
hypometabolism [22], other factors such as APOE genotype and tau deposition 
affect the distribution of amyloid. Whole-brain amyloid positivity appears a 
greater determinant of gross cognitive dysfunction compared to the precise areal 
distribution; however, measures of non-crystallized intelligence (e.g., executive 
functions, reasoning, problem solving) are sensitive to the amount deposited [19]. 
It is not unusual to find a dissociation between amyloid deposition and metabolic 
hypometabolism or between amyloid deposition and cortical thinning [25–27]. As 
discussed below (Section 6.1), while clinically normal elders can show significant 
correlation between thinning and amyloid deposition in the PCC, they do not show 
a significant association between these biomarkers in the ACC [28]. Amyloid depo-
sition although predictive of future cognitive decline correlates poorly with actual 
cognitive status: the number of neurofibrillary tangles (NFTs), not senile amyloid 
plaques, correlates with cognitive status before death [29]. Classically, amyloid 
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is necessary but not sufficient for the diagnosis of AD; tau with neurofibrillary 
changes is also required [30, 31]. However, over one-third of patients with clinically 
diagnosed mild to moderate AD who do not carry an APOE4 allele show minimal 
amyloid yet extensive neurofibrillary degeneration on autopsy [32]. Whether this 
group is pathophysiologically an AD variant or a tauopathy remains unclear [32, 33].
Deposits of tau generally follow amyloid. Immunohistochemical studies of tau 
and neuroimaging of humans using tau radiotracers converge on tau’s more restricted 
involvement in the temporal lobe in early AD [17, 34, 35]. Tau does not follow the 
global miliary pattern of amyloid neocortical involvement with disease progression. 
Tau’s presence more directly correlates with cognitive dysfunction and cortical thin-
ning than does amyloid [14, 36]. These changes reflect presumably the final stages 
of neurodegeneration. Unlike amyloid deposition, the localization of tau mirrors the 
clinical and neuroanatomical phenotypic variability of AD [37, 38]. Longitudinal 
data of both amyloid and tau have enabled assessment of directionality of biomarker 
spread as well as potential relationships with gene expression [39]. APOE played a 
central role in the lipid interactome affecting both Aß and tau spread, while tau- and 
Aß-risk genes differentially contributed to the specific spread of each biomarker.
3. The default mode network (DMN)
The distribution of amyloid has been noted to overlap with the neural system 
related to the default mode of brain function [5]. The observation has prompted 
hypotheses about the relationship of neural activity, the default mode network, and 
AD that continue to evolve.
PET studies have shown a broad region of relative deactivation in resting states 
compared to active states with greatest deactivation within the ventromedial 
prefrontal cortex (VMPFC) with peak minimum at Brodmann area 10 (BA10; 
Figure 1) [40]. Additional regions showing deactivations localized bilaterally to the 
inferior and superior frontal cortex, PCC/precuneus, prefrontal cortex, inferior 
parietal cortex, and several temporal areas.
The deactivation in the VMPFC during rest was shown not to reflect a relative 
activation as the OEF did not change significantly from whole-brain (e.g., Figure 1;  
Figure 1. 
Transverse sections (z = −6) of stereotactically normalized parametric data showing convergence across 
studies between CBF change and FC as well as relative stability of OEF. Left: Region of common relative CBF 
deactivation (VMPFC) in mega image contrast between active scans and passive scans (peak Z-score − 7.7; 
modified from [40]); middle: Default mode oxygen extraction fraction during rest with eyes closed; uniform 
OEF; no OEF increase in VMPFC [41]. Right: Resting state FC of the VMPFC with the DMN [49]. Middle & 
left: Copyright (2003) National Academy of Sciences, U.S.A.
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Raichle et al. [41]). If the VMPFC were activated, it should show increased OEF 
(as some regions in the visual cortices, see red color). The activated network during 
passive tasks was hypothesized instead to reflect a return to baseline or default 
mode network (DMN) that was interrupted by active tasks. The regional specificity 
of the DMN suggested some ill-defined brain function.
The DMN can be detected even in the presence of deep anesthesia suggesting 
a degree of invariance with respect to consciousness possibly reflecting intrinsic 
brain organization such as anatomical connectivity [42]. The VMPFC becomes 
more active not only at rest relative to other active task states (e.g., attentional) but 
also during a variety of other conditions where attention is directed away from the 
external environment. Such states include introspection, “mind wandering” [43], 
self-appraisal or introspection [44], stimulus independent thought [45], episodic 
future simulation, trait emotional self-awareness [46], and interoceptive tasks (e.g., 
recall of visceral information) [47]. As this book notes, these are reflections of the 
“autobiographical self.”
Previous work in the mid to late 1990s observed physiological fluctuations 
occurring during active states and even during rest in the MR blood oxygen level 
dependent (BOLD) signal in humans and in CBF in rodents that were correlated 
at low frequency (0.1 Hz) across regions known to have anatomical and functional 
relatedness [48]. However, it remained unclear how these temporal signals related 
to the DMN as defined from PET studies.
Remarkably, when the VMPFC region in the DMN (showing relative deactiva-
tion during active tasks using PET) was used as a seed region to correlate BOLD 
signals throughout the brain, a network surface based on interregional temporal 
coherence of the BOLD MR signal that was visually superimposable on the 
DMN. Use of a spiral MR pulse sequence avoiding signal dropout in ventral prefron-
tal regions enabled good signal recovery within VMPFC (Figure 1 [49]). Subsequent 
fMRI studies examining resting state networks displayed a more variable pattern in 
the medial prefrontal regions frequently showing more dorsal localization [50–52]. 
The significance of this disparity is unclear but may relate to low signal recovery 
with fMRI in ventral brain regions or other subnetworks (see below).
The analysis of BOLD data from the resting state using independent compo-
nent analysis of FC identified numerous subnetworks showing both anatomical 
(known afferent and efferent anatomical projections) and functional (coactiva-
tion during tasks) architecture converging with other datasets (Figure 2) [53]. The 
four principal RSNs are the dorsal attention network (DAN), DMN (as above), 
salience network (SAL; also termed cingulo-opercular), and bilateral frontopa-
rietal control network (FPC). The latter is sometimes segmented to dorsal and 
ventral systems [54].
The precise components of these RSNs need further refinement. For example, 
how does the “anterior medial prefrontal cortex” relate to VMPFC, pgACC, dACC, 
and medial superior frontal gyrus? What elementary cognitive operations do these 
different areas serve? Similarly, how does the “PCC/precuneus” relate to the vari-
ous medial parietal subregions, and what functions do they serve? In this regard, 
preliminary dissection divides the PCC into dorsal and ventral regions, each with 
two additional subregions that in turn connect with other differing cortical projec-
tion regions [55].
These four major networks based on data averaged across individuals only hint 
at the complexity on a more fine-grained analysis. ICA can produce many more net-
works, and the Human Connectome Project points to 180 parcels per hemisphere 
[56]. When resting BOLD is collected over many hours for one individual, much 
more complex, interdigitated, parallel, distributed networks become apparent 
without the blurring caused by inter-subject averaging [57].
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Data on the effects of aging and amyloid/tau deposition on these subnetworks 
continue to accrue, but there appears differential vulnerability of different subnet-
works. For example, amyloid decreased the FC of the DMN subnetworks relevant to 
episodic memory (PCC, angular gyrus, VMPFC) while increasing FC in dorsolateral 
and anterior medial prefrontal cortices as well as lateral temporal regions [58]. The 
latter regions were interpreted as reflecting compensatory responses to the amyloid-
related dysfunction in the memory subnetworks. Furthermore, the mere presence 
of biomarkers such as amyloid in preclinical AD can confound FC findings within 
and across RSNs. Cognitively normal subjects without vs. with amyloid positivity 
show small vs. large age-related changes in RSN functional, respectively [59].
The DMN shares considerable connectivity with the hippocampus [60, 61]. The 
DMN couples with different sectors of the hippocampus [62] through the parahip-
pocampal gyrus depending on task context during rest [63]; spontaneous, uncon-
strained thought (e.g., thinking about one’s past or future [64]); episodic memory 
retrieval [65]; and associative episodic memory encoding [63]. This network 
becomes disrupted early occurring both in preclinical and early AD (see Section 6, 
below) [60, 66].
4. Cerebral energetics
The energetic balance sheet indicates a large part of oxidative metabolism main-
tains the resting state [67–69]. The classic work of Seymour Kety showed oxygen 
consumption in the brain differed little across a wide variety of abnormal mental 
states such as in psychosis, whether in schizophrenic decompensation or acute 
drug intoxication [70]. In response to external stimulation, the brain only increases 
oxygen consumption by 5% [71]. Similarly, few differences in oxygen consumption 
occur between sleep vs. wakefulness [72]. Although the bulk of brain work at rest 
and on activation derives from oxidative phosphorylation [71], the metabolism 
hypothesis of AD focuses on a specific metabolic pathway: AG (i.e., glycolysis in the 
presence of adequate levels of oxygen; i.e., nonoxidative metabolism of glucose [73]).
Regions high in oxidative phosphorylation do not necessarily have high rates 
of AG. As an example, the visual cortex has very high glucose metabolism; high 
cerebral blood flow (CBF); high oxidative metabolism (cerebral metabolic rate for 
oxygen) with high levels of cytochrome oxidase; but low AG [73]. The focus on AG 
follows from the visual cortex having relative resistance to amyloid deposition and 
being one of the regions showing little decrease in metabolism with aging. In con-
trast, the PCC has high flow, oxidative metabolism, glucose metabolism, and high 
Figure 2. 
Four major RSNs revealed by ICA: DAN, dorsal attention network; DMN, default mode network; SN, salience 
network (also called cingulo-opercular network); right FPC, frontoparietal control network. Modified from [54].
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AG [73]. As summarized above, the PCC is very susceptible to amyloid deposition 
and is among the earliest dysfunctional regions in AD. These observations further 
refined the metabolism hypothesis of AD.
In a group of mostly cognitively intact elders, those globally without amyloid did 
not have tau accumulation in areas prone toward tau deposits (precuneus, amyg-
dala, entorhinal, inferior temporal, inferior and superior parietal, fusiform, and lat-
eral occipital cortices) and did not have decreased CMRO or AG [69]. They showed 
a positive correlation between AG and CMRglu; no correlations surfaced between 
CMRO, CMRglu, or tau deposition. In contrast, those who were amyloid positive 
globally showed an inverse relationship between tau and AG but not between tau 
and CMRO or CMRglu. These data suggest the loss of AG in tau-prone regions with 
tau accumulation leads to decreased plasticity and decreased neuroprotection (i.e., 
decreased redox buffering) leading to accelerated tauopathy.
5. Role of DMN and amyloid
The default network shows overlap with brain regions high in AG which in 
turn show overlap with areas of amyloid deposition in AD [74]. Unlike oxidative 
phosphorylation used to generate energy, AG proceeds less efficiently energetically 
(2 ATP vs. 38 ATP per glucose molecule) but more suitably for reduction of bio-
molecules for anabolism [75]. Anabolism that appears to play a much greater role in 
early human development could also provide, albeit to a lesser extent, the substrates 
for plasticity related to learning and memory in adults [76, 77]. The metabolism 
hypothesis is important because it motivates the search for AD pathophysiology 
beyond amyloid deposition to some aspect of cerebral metabolism particularly 
AG. Normal aging is associated with the loss of AG in regions which sustain higher 
levels of AG in youth; these are the very regions showing susceptibility to amyloid 
deposition [7]. The metabolism hypothesis could help explain why the frequency of 
AD rises relentlessly with aging and oxidative stress.
Several lines of evidence support the metabolism hypothesis of AD through 
altered processing of Aß [78]. The processing pathways include both increased 
production and decreased clearance. Most AD-causing dominant mutations in APP, 
PSEN1, and PSEN2 increase Aß production [79]. One mutation that is protective for 
AD occurs near the APP BACE1 cleavage site impairing γ cleavage; it is associated 
in vitro with decreased amyloidogenic peptides [80]. Likewise, vibrissal stimulation 
of APP transgenic mice increases Aß in interstitial CSF and amyloid plaques while 
decreasing lactate, a proxy for neural activity [81]. In-vitro mouse slice preparations 
show based on microdialysis rapid increases in Aß correlated with synaptic activity 
[82]. In cognitively normal older adults, greater hippocampal activity during encod-
ing at baseline correlates with longitudinal amyloid deposition and diminished 
cognitive performance [83]. APOE, the major risk locus for AD, plays a key role 
in Aß aggregation, fibrillogenesis, and maturation of neuritic plaques [84]. AD 
patients relative to controls have decreased clearance of CSF Aß with normal rate of 
Aß production [85].
6. Gaps in the metabolism hypothesis
Here, issues informing discussions about the amyloid hypothesis of AD and 
relationships to cerebral metabolism are outlined. These raise questions about 
the strong version of the metabolism hypothesis and its implications, or at least 
suggest a need for revision. Significant circumstantial evidence centers on several 
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observations: (1) normal cognitive aging; (2) familial AD; (3) healthy individuals 
at very high risk of AD (APOE*E4 homozygotes); (4) the evolving role of tau in 
AD; (5) interrelationships between amyloid and tau in AD pathology; and (6) the 
implications for cognitive function in “real time.”
6.1 The metabolism hypothesis and cognitive aging
The metabolism hypothesis suggests that if chronically elevated levels of resting 
brain activity over the lifetime drive Aß deposition with attendant cognitive dys-
function leading to AD, there should be amyloid deposition during healthy aging 
as well. Based on this mechanism, the PCC region should show major hypometabo-
lism, atrophy, and amyloid deposition as seen in early AD [21, 86–88].
Yet, this phenomenon is not observed. The PCC in normal aging shows relative 
preservation (Figure 3). Among the regions showing the least decline in metabo-
lism with aging is the PCC. Older healthy adults show minimal PCC atrophy rates 
over 12 months [89]. Older healthy adults, especially E4 non-carriers, do not show 
amyloid deposition in the PCC [90–92]. Young adult E4 carriers with positive 
family history of AD and at high risk of future AD already show PCC hypome-
tabolism implying DMN hyperactivity related to AD must have occurred before 
then [93]. Of note, older healthy E4 non-carriers begin to show amyloid positivity 
at around 71 years of age, while the E4 carriers develop amyloid positivity about 
20 years earlier. Interestingly, when separating the independent effects of aging vs. 
E4 load, amyloid deposition shows a more frontal involvement. Of note, the effects 
of aging and E4 load interact: the peak hazard ratio occurs ~60 years of age and 
declines thereafter; E4 is a risk factor for AD even for younger adults (<65 years) 
[94]. Furthermore, resting connectivity of the PCC/precuneus region to the ACC 
is reduced in older healthy adults who carry E4 even in the absence of detectable 
fibrillar amyloid or decreased CSF Aß42 suggesting both Aß-dependent and 
Aß-independent aging-related mechanisms [95].
The principal locus of declining metabolism in healthy elders does not map to 
the PCC but localizes instead to the ACC (Figure 3) [96–101]. ACC hypometabo-
lism correlates also with aging-related decline in cognitive function [99]. Whereas 
Figure 3. 
Decline of brain activity with aging in healthy volunteers. Voxel-wise Pearson correlation (r) map of glucose 
uptake vs. age in stereotactically normalized brain (3D-SSP; S. Minoshima, University of Utah). A, lateral; B, 
medial; C, dorsal (left)/ventral (right). Color scale shows peak r = −0.8. Note the greatest decline in glucose uptake 
with age localizes to the ACC (BA 32/9; region 1). A midline circuit (regions 1-3) includes dorsomedial thalamus 
and basal forebrain/subgenual cingulate; the metabolism in this circuit correlates with declining executive function 
(verbal fluency). Other regions with lower correlations are not associated with cognitive performance. Reprinted 
from Neuroimage, Vol 35(3), Pardo JV et al., Where the brain grows old: Decline in anterior cingulate and medial 
prefrontal function with normal aging. Copyright (2007), with permission from Elsevier.
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AG localizes to ACC, PCC, and parietal regions, loss of regions high in AG during 
youth appears to occur in all three regions without selectivity for any one of these 
regions [76]. So, unless AD per se involves hyperactivity of the DMN beyond that 
in normal elders for which there is no evidence, the hypothesis does not address the 
inconsistency between mechanisms of cognitive aging versus AD to account for the 
observed dissociation between ACC and PCC findings.
Several observations related to cognitive aging need reconciliation with the 
metabolism hypothesis. Healthy elders free from amyloid deposition show a 
remarkable disconnection between the anterior and posterior default networks 
(i.e., ACC and PCC) [102]. Yet, nothing about the metabolism hypothesis explains 
why DMN regions with high AG, where amyloid will be deposited as AD develops, 
should disconnect—both regions should show aging-related hypometabolism as a 
result of white matter damage. Similarly, cognitively normal elders not at high risk 
for AD (no E4) show increases and decreases within anterior DMN connectivity, 
while showing only decreases in posterior DMN FC [103]. Cognitively intact elders 
with minimal amyloid deposition without E4 have greater connectivity of the ACC 
to the precuneus than those with E4 [95]. The aging-related anterior vs. posterior 
dissociations in connectivity within DMN networks remain theoretically difficult to 
predict based solely on the metabolism hypothesis.
The ACC also has high glucose metabolism, flow, oxygen consumption, and 
AG; yet, the ACC does not show amyloid deposition akin to the PCC with healthy 
aging (those >60 years without amyloid positive scans [23]). Thus, chronic neural 
activity along with AG during the lifespan per se is not sufficient to lay down 
amyloid. Just as PCC hypometabolism marks focal atrophy early in AD, the region 
of ACC hypometabolism with aging should likewise display cortical thinning. 
However, several large studies do not support the prediction [104, 105], although 
not all findings are convergent [106]. Additionally, recent studies of tau deposition 
in preclinical AD show early deposition in the PCC but not in the ACC [107]. Those 
elders with cognitive function akin to much younger subjects (i.e., “SuperAgers”) 
show thickening of the ACC and increased spindle cells suggestive of plasticity with 
aging; or alternatively, “SuperAgers” may be endowed with ACC thickening before 
aging [108, 109]. Also, age can confound years of education; the latter is associated 
with increased ACC thickness and metabolism [110, 111]. However, studies of the 
effects of aerobic fitness exercise on cognition and cortex show ACC thickening in 
older adults in support of the potential for plasticity in this region [112].
A clear dissociation can arise also between amyloid deposition and FDG metabo-
lism in the ACC in AD that is difficult to explain with the metabolism hypothesis. 
Patients who initially had mild AD, as confirmed with metabolic and amyloid 
biomarkers, were followed for 2 years along with a matched, amyloid negative 
control group. Despite extensive amyloid deposition in the ACC of the AD patients, 
no hypometabolism colocalized in the ACC during follow-up [22]. The aging-
related ACC hypometabolism noted previously likely led to a floor effect across 
groups. Likewise, aging-related ACC hypometabolism would tend to spare amyloid 
deposition in patients appearing inconsistent with the metabolism hypothesis given 
extensive amyloid involvement of the ACC in AD.
6.2 The metabolism hypothesis and autosomal dominant AD
A corollary of the metabolism hypothesis suggests those with familial AD 
would show similar patterns of hypometabolism and amyloid deposition to 
late-onset, sporadic AD. However, those with mutations (APP, PSEN1, PSEN2) 
show greatest amyloid deposition in the basal ganglia, a site that only becomes 
involved late in typical sporadic AD [113–115]. However, the specific pattern of 
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amyloid deposition may depend to some extent on the specific mutation. For 
example, the PS1 mutation, E280A, shows amyloid deposition more like late-
onset sporadic AD than many other mutations with early onset. This variability 
may not surprise given the complexity of the underlying biology of different 
mutations in PS1 [116].
6.3 Role of APOE genotype in the metabolism hypothesis
If regional brain activity drives amyloid deposition in the pattern seen in AD, then 
the AD metabolic pattern should arise in those at highest risk for the future develop-
ment of AD—asymptomatic APOE*E4 homozygotes, who have a 12-fold increased 
risk of LOAD. So far, there are seven such individuals in the Alzheimer’s Disease 
Neuroimaging Initiative’s (ADNI) database. Their pattern of amyloid deposition 
highlights bilateral lenticular nuclei and the ACC/medial prefrontal involvement with 
the PCC notably unaffected (see Figure 3). In fact, the deposition of amyloid in the 
homozygotes is reminiscent of that seen in Down’s syndrome and most mutations 
found in autosomal dominantly inherited forms of AD arising in APP, PS1, or PS2 
[113–115, 117]. This pattern of amyloid deposition in E4 homozygotes is consistent 
with findings reported previously in an independent group of eight homozygotes [91].
6.4 Role of tau in the metabolism hypothesis
Another difficulty with the metabolism hypothesis of AD is the notable absence 
of tau involvement in this theory. The role of tau, its modifications, and its etiologic 
role in neurodegeneration in AD has been reviewed previously [118]. Although the 
metabolism hypothesis of AD focuses on amyloid deposition, there is increasing evi-
dence that tau plays at least as great if not greater etiopathological role. Of interest in 
this context, recent studies show tau deposition during preclinical AD in the PCC; the 
metabolism hypothesis cannot explain this dissociation between PCC and ACC [107].
AD cases with neurofibrillary changes (neuritic plaques, neurofibrillary tangles, 
neurofibrillary threads, tau tangles) typically show extensive amyloid deposition. 
However, not all cases with extensive amyloid deposition show neurofibrillary 
changes [17]. Amyloid deposits and neuritic plaques vary widely across individuals 
both temporally and regionally; so, they do not provide useful biomarkers for stag-
ing of AD [17]. In contrast, the distribution of tau is consistent across individuals 
and provides useful staging of disease progression [17].
Hyper-phosphorylated intraneuronal tau (“pretangle”) has been reported even in 
young adults in the absence of amyloid particularly in subcortical nuclei such as the 
locus coeruleus [119]. The significance of these findings in the context of AD remains 
uncertain as the pretangle material may be transient, related incidentally to other pro-
cesses (e.g., traumatic brain injury), or the earliest manifestations of AD. Furthermore, 
studies of transgenic mice with APOE isoform knock-in and APOE knock-out show 
that even in the absence of amyloid, E4 is particularly neurotoxic in mice with mutant 
tau transgenes, and this toxicity is in part mediated by neuroinflammation via the 
innate immune system produced by microglia and type A1 astrocytes [120].
A recent study identified the significant role of tau in the context of amyloid 
deposition [121]. High resolution fMRI of cerebral blood volume (CBV), coupled 
to regional metabolism, mapped the earliest changes in preclinical AD to lateral 
entorhinal (LEC), transentorhinal, and perirhinal cortices, as predicted from 
neuropathological studies [17]. The former region’s CBV correlated significantly 
with a test of delayed retention. Three lines of mice were generated with dif-
ferential expression in entorhinal cortex of pathological human APP, tau, or both 
transgenes.
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Mice with mutant entorhinal tau alone, but not mutant APP alone, had dimin-
ished CBV in LEC with aging [121]. The double mutant had decreased LEC CBV 
with aging compared to the single mutants and other controls thereby demonstrat-
ing that APP increased tau-related metabolic dysfunction. Decreased CBV in aged 
double mutant spread even to posterior parietal cortex, a pattern reminiscent of 
human AD. APP immunohistochemistry of older mice showed no changes between 
mutant APP and double mutant mice; the label localized mostly to entorhinal 
cortex. However, tau immunohistochemistry of older mice showed increased signal 
in the double mutants with the suggestion of relocalization of phospho-tau from 
neuropil to the somatodendritic compartment.
The differing roles of amyloid and tau in the evolution of AD were recently high-
lighted in cognitively intact elders [58]. Those positive for amyloid (Aß+) showed 
hyperconnectivity within DMN and SN when tau deposits were low. In contrast, 
the Aß + subjects showed decreased FC with increasing tau deposition. Thus, 
the effects of PET biomarkers on FC appear complex and likely involve multiple 
neuropathological processes.
These data make clear that tau cannot be ignored in understanding the ontogen-
esis of AD. The metabolism hypothesis needs modification for relevance beyond 
amyloid deposition to AD pathophysiology.
6.5 Cognitive processing in “real time”
The biomarkers discussed so far are not dynamic in terms of real time. These 
scans, even when measured during rest, probe parameters over many minutes—
totally divorced from cognitive processes that occur at the scale of milliseconds to 
seconds. Recent studies hint that the metabolism hypothesis has relevance to the 
latter time scale.
As mentioned in Section 5, lactate is a proxy for neural activation and through 
regulation of NADH/NAD+ becomes a modulator of rCBF in response to activation 
[122]. Astrocytes on activation show a metabolic switch toward AG shifting oxy-
genation from astrocytes to neurons [123]. In turn, lactate produced through AG is 
critical for memory formation [124]. Because AG can provide reducing equivalents 
for biosynthesis of macromolecules for plasticity, learning tasks demonstrate focal 
increases in AG on-line with experience-dependent plasticity [77]. The elevation 
in AG can persist for many minutes after an activation task [125]. How amyloid 
impacts real-time learning through changes in AG remains to be elucidated.
Preliminary studies have examined using magnetoencephalography (MEG) 
oscillatory power in real time in cognitively normal elders either with amyloid 
deposition (“preclinical AD”) or without amyloid deposition [126]. Increases in 
power in the alpha range in the amyloid-positive preclinical cases at rest local-
ized over the ACC and correlated with increased glucose metabolism. These 
metabolic changes did not yet correlate with structural atrophy or cognitive 
decline. The findings begin to define the earliest on-line physiological changes in 
preclinical AD. Similarly, increased functional connectivity at rest localized to the 
ACC. Proposed hypotheses include cognitive compensation (i.e., cognitive reserve) 
or amyloid-related hyper-excitability in preclinical AD [58, 127].
7. Concluding remarks about the metabolism hypothesis
The observations reviewed above argue that even if chronic neural activity in 
the DMN biases Aß production and clearance toward amyloid deposition, differ-
ent mechanisms participate in Aß localization in normal elderly, E4 homozygotes, 
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familial dominant AD, and sporadic AD. Further, tau has reached a new level of 
significance in AD pathophysiology. The cellular and molecular mechanisms of 
human Aß deposition and the relationship to AD appear pleiomorphic and complex 
defy so far simplistic explanations for a complex disease. However, given the recent 
advances in multimodal molecular imaging (amyloid, tau, neuroinflammation, 
etc.), the story is likely to evolve quickly.
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